Long noncoding RNA OIP5-AS1 promotes the progression of oral squamous cell carcinoma via regulating miR-338-3p/NRP1 axis - 18/09/19

pages | 7 |
Iconographies | 5 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | OIP5-AS1 is upregulated in OSCC tissues and cell lines. |
• | OIP5-AS1 promotes the progression of OSCC. |
• | OIP5-AS1 exerts an oncogenic role in OSCC by regulating miR-338-3p/NRP1 axis. |
Abstract |
Opa-interacting protein 5 antisense RNA 1 (OIP5-AS1), a novel identified long noncoding RNA (lncRNA), has been suggested to serve as oncogene in multiple cancers. However, the functional involvement of OIP5-AS1 in oral squamous cell carcinoma (OSCC) was still unknown. The aims of this study were to investigate the functional role of OIP5-AS1 in OSCC and explore its potential mechanism. We found that OIP5-AS1 was up-regulated in OSCC tissues compared with adjacent non-tumor tissues. Loss-of-function experiments revealed that OIP5-AS1 knockdown significantly inhibited OSCC cell proliferation, migration and invasion in vitro, and retarded tumor growth in vivo. Mechanistically, OIP5-AS1 serves as a competing endogenous RNA of miR-338-3p and modulates the expression of neuropilin1 (NRP1), which has been identified as a downstream target gene of miR-338-3p in OSCC. Moreover, downregulation of miR-338-3p or overexpression of NRP1 partly reversed the inhibitory effect of OIP5-AS1 depletion on cell proliferation, migration and invasion. The current results provide evidences for the role of OIP5-AS1 in promoting OSCC progression by regulating miR-338-3p/NRP1 axis and suggest OIP5-AS1 as a potential therapy target for OSCC.
Le texte complet de cet article est disponible en PDF.Keywords : Oral squamous cell carcinoma, OIP5-AS1, miR-338-3p, NRP1
Plan
Vol 118
Article 109259- octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?